Antifungal prophylaxis with anidulafungin to minimize drug interactions with an antiepileptic treatment in a hematopoietic stem cell transplant recipient. (13th June 2015)

• Record Type: Journal Article
• Authors: Feliu, J.; Del Pozo, J. L.; Azanza, J. R.; García‐Muñoz, R.; Zabalza, A.; Gorosquieta, A.; Pérez‐Equiza, E.; Olavarría, E.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 40:Number 5(2015:Oct.)
• Page Start: 601
• Page End: 603
• Publication Date: 2015-06-13
• Subjects: Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.12299
• Languages: English
• ISSNs: 0269-4727

Abstract

<abstract abstract-type="main" id="jcpt12299-abs-0001"> <title>Summary</title> <sec id="jcpt12299-sec-0001" sec-type="section"> <title>What is known and objective</title> <p>Invasive fungal infections are a major cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). This provides a clear rationale for antifungal prophylaxis in this population. A concern is the potential for drug interactions, given that most of antifungals are metabolized through the P450 cytochrome system.</p> </sec> <sec id="jcpt12299-sec-0002" sec-type="section"> <title>Case summary</title> <p>We present a case of a 33‐year‐old woman, with a past history of high‐risk epilepsy, who underwent allogeneic HSCT for a myelodysplastic syndrome. Anidulafungin was successfully used as antifungal prophylaxis to minimize drug interactions with her antiepileptic treatment.</p> </sec> <sec id="jcpt12299-sec-0003" sec-type="section"> <title>What is new and conclusion</title> <p>This is the first reported case of antifungal prophylaxis with this echinocandin in HSCT. Anidulafungin may be an option in transplant recipients with multiple risk factors for drug interactions.</p> </sec> </abstract>